The proof of concept has been positively confirmed by early access customers. Dr. Matthew Huentelman, an investigator and lead collaborator at the Translational Genomics Research Institute (TGen) in Phoenix, AZ, was one of the first researchers to use HybSelect. His laboratory uses state-of-the-art techniques to pin-point differences in genes and pathways that contribute to the development and progression of Alzheimer's disease. "We are really excited about the high enrichment factor and the depth of coverage of the targeted sequences that can be achieved using HybSelect from febit. The short hands-on time and ease of use reinforce our intentions to use this new technology for further studies," said Dr. Huentelman.
HybSelect will be also employed in the newly developed Biomarker Discovery Center Heidelberg for the detection of novel tumor markers. Within the European READNA-consortium (REvolutionary Approaches and Devices for Nucleic Acid analysis) HybSelect will support the selection and enrichment of specific gene loci for Next Generation Sequencers.
The new technology is available as a protocol for febit's Geniom RT Analyzer, or as a full service including Next-Gen sequencing from febit. HybSelect is optimized for the Illumina GAII sequencing system, and will be available for other sequencing platforms soon.
HybSelect will be presented at
Copyright©2009 PR Newswire.
All rights reserved